Amendment #1368 to H5500

Naloxone Procurement

Ms. Kilcoyne of Clinton moves to amend the bill in section 2, in item 4590-0930, by adding the following: "provided, that when sourcing intranasal naloxone products, the department of public health shall apply evaluation criteria intended to expand access to lifesaving naloxone, strengthen supply reliability for statewide distribution, and reduce product expiration waste, and shall give preference to drug manufacturers that meet the following criteria: at least two continuous years of experience manufacturing and assembling intranasal naloxone products in the United States; demonstrated capacity to ship intranasal naloxone products to dispersed sites across the state; a consistent history of maintaining publicly accessible financial, governance, and operational information, with independent verification as required under applicable federal and state laws or regulations; an established operational presence in the state; demonstrated ability to provide distribution data insights and educational and training materials; and ability to provide the maximum available shelf life from date of manufacturing".